adherence; bone marker; compliance; feedback; ibandronate; osteoporosis
Abstract :
[en] Aim: This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker
feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.
Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study
conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (£ 85 years old) who were
naı¨ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at
3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and
adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate
treatment were also assessed.
Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients
were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels
were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their
osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients.
Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to
once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence,
but increased treatment satisfaction.
Disciplines :
Rheumatology
Author, co-author :
Kung, Annie Wai-Chee
Rachman, A Ichramsjah
Adam, MF John
Roeshadi, Djoko
Torralba, Tito
Navarra, Sandra
Gamilla, Zayda
Cañete, Arthur
de la Rosa, Miles
Tsai, KehSung
Lin, Hsiao-Yi
Soong, Yung Kuei
Lan, Joung-Liang
Hsu, Horng-Chaung
Tu, Shih-Te
Lin, Ruey-Mo
Yuktanandana, Pongsak
Songpatanasilp, Thawee
Ngarmukos, Srihatach
Soontrapa, Sugree
Soontrapa, Suppasin
Rojanasthien, Sattaya
Luevitoonvechkij, Sirichai
Leerapan, Taninnit
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique - Département de mathématique
Vanbelle, Sophie ; Université de Liège - ULiège > Département de mathématique > Département de mathématique
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761-7.
Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359, 2018-26.
Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15, M406. (Abstract).
Finigan J, Bainbridge PR, Eastell R (2001) Adherence to osteoporosis therapies. Osteoporos Int 12, S48-9, P110 (Abstract).
Caro J, Ishak K, Huybrechts K, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15, 1003-8.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2003) Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int 14, PL6. (Abstract).
Sambrook PN, Rodriguez JP, Wasnich RD, et al. (2004) Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 15, 483-8.
Bone HG, Hosking D, Devogelaer JP, et al. (2004) Ten years'experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350, 1189-99.
Sorensen OH, Crawford GM, Mulder H, et al. (2003) Long-term efficacy of risedronate: A 5-year placebo controlled clinical experience. Bone 32, 120-6.
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14, 259-62.
World Health Organization (2003) Adherence to long-term therapies. Evidence for action. WHO/MNC/03.01.
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of Biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11, S2-17.
Looker AC, Bauer DC, Chesnut CH III, et al. (2000) Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11, 467-80.
Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11, S30-44.
Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30, 886-90.
Flood EM, Beusterien KM, Green H, et al. (2006) Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4, 42.
F Hoffmann-La Roche Ltd. MEDTAP Institute at United Biosource Corp. OPPS Scoring guideline, Version 2.0 as of 08.09.05.
World Health Organization (2003) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921, 1-164.
Reginster JY, Lecart MP (2004) Treatment of osteoporosis with bisphosphonates - do compliance and persistence matter? Business Briefing: Long-term Healthcare 1-9.
McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-87.
Solomon DH, Avorn J, Katz JN, et al. (2005) Compliance with osteoporosis medications. Arch Intern Med 165, 2414-9.
Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with anti-resorptive treatment for post-menopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 89, 1117-23.
Delmas PD, Vrijens B, Eastell R, et al. (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92, 1296-304.
McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoprosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23, 3137-52.
Bonnick SL, Martens M, Civitelli R, Friend K, Silverman S (2007) Women with postmenopausal osteoporosis or osteopenia previously receiving weekly alendronate or risedronate are more satisfied with monthly ibandronate. Calcif Tissue Int 80(Suppl. 1), s118 (Abstract P308-T).
Emkey R, Koltun W, Beusterien K, et al. (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis. Curr Med Res Opin 21, 1895-903.
Miller PD, McClung MR, Macovei L, et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20, 1315-22.